{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:01:30Z","timestamp":1774630890947,"version":"3.50.1"},"reference-count":9,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jhepr.2024.101291","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T16:36:30Z","timestamp":1732898190000},"page":"101291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Should all pediatric patients with type 1 autoimmune hepatitis be screened for inflammatory bowel disease?"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4146-1335","authenticated-orcid":false,"given":"Richard","family":"Kellermayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jhepr.2024.101291_bib1","article-title":"Biliary disease progression in childhood onset autoimmune liver disease: a 30-year follow-up into adulthood","volume":"6","author":"Warner","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2024.101291_bib2","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000926","article-title":"Identifying a therapeutic window of opportunity for people living with primary sclerosing cholangitis: embryology and the overlap of inflammatory bowel disease with immune-mediated liver injury","author":"Kellermayer","year":"2024","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101291_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5009\/gnl16510","article-title":"Inflammatory bowel disease and primary sclerosing cholangitis: a review of the phenotype and associated specific features","volume":"12","author":"Palmela","year":"2018","journal-title":"Gut Liver"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101291_bib4","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MPG.0000000000001531","article-title":"Unique inflammatory bowel disease phenotype of pediatric primary sclerosing cholangitis: a Single-Center Study","volume":"65","author":"Shiau","year":"2017","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"7","key":"10.1016\/j.jhepr.2024.101291_bib5","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.cgh.2019.08.048","article-title":"Primary sclerosing cholangitis in children with inflammatory bowel diseases is associated with milder clinical activity but more frequent subclinical inflammation and growth impairment","volume":"18","author":"Ricciuto","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101291_bib6","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3748\/wjg.v21.i6.1956","article-title":"Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis","volume":"21","author":"de Vries","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jhepr.2024.101291_bib7","first-page":"303","article-title":"Fecal calprotectin for the evaluation of inflammatory bowel disease","volume":"104","author":"Bryce","year":"2021","journal-title":"Am Fam Physician"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101291_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.jhepr.2024.101291_bib9","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/apt.17936","article-title":"Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): a matched analysis from the Paediatric PSC Consortium","volume":"59","author":"Ricciuto","year":"2024","journal-title":"Aliment Pharmacol Ther"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924002957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924002957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:27:57Z","timestamp":1741652877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555924002957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2589555924002957"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101291","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should all pediatric patients with type 1 autoimmune hepatitis be screened for inflammatory bowel disease?","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100901","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101291"}}